Company Encyclopedia
View More
name
iShares Biotechnology ETF
IBB.US
News
View More

Pharmaceutical Stocks To Add to Your Watchlist - December 20th

MarketBeat's stock screener tool highlights seven pharmaceutical stocks to watch: Eli Lilly, Alnylam Pharmaceuticals, AbbVie, Insmed, Gilead Sciences, Vertex Pharmaceuticals, and Pfizer. These stocks are noted for their potential growth driven by successful drug pipelines, despite risks like regulatory challenges and patent expiries. The companies have recently seen high trading volumes, indicating investor interest. Each company is involved in developing and commercializing various pharmaceuticals and therapies.

Market Beat·
US
LLY
+1.38%
US
GILD
+2.32%
Market Beat·
US
LLY
+1.38%
US
GILD
+2.32%

Did Strong New Signatera ctDNA Data Just Shift Natera’s (NTRA) Investment Narrative?

Natera's new clinical data strengthens the investment narrative for its Signatera ctDNA assays, highlighting their role in guiding treatment choices and refining recurrence risk. Despite growing validation, profitability risks remain due to heavy investment and potential reimbursement shifts. Natera projects $3 billion revenue by 2028, with fair value estimates ranging widely. Investors should consider clinical adoption and reimbursement as key catalysts for future performance.

Simplywall·
US
NTRA
+3.21%
Simplywall·
US
NTRA
+3.21%

Regeneron Pharmaceuticals (NASDAQ:REGN) Downgraded to Hold Rating by Wall Street Zen

Wall Street Zen downgraded Regeneron Pharmaceuticals from a "buy" to a "hold" rating. Other analysts have varied opinions, with some upgrading to "strong-buy" and others adjusting price targets. The stock has a consensus "Moderate Buy" rating with a target price of $779.45. Recent insider trading and institutional investments are also noted.

Market Beat·
US
REGN
+2.57%
Market Beat·
US
REGN
+2.57%

The Ice Cube Is Melting: Here's What Happens Next

The article analyzes three trade ideas focusing on time decay: Gilead's diagonal spread is profitable, Valero's put credit spread is losing, and ExxonMobil's calls are underwater. Gilead benefits from positive time decay, while Valero and ExxonMobil face challenges due to stock movements. The piece emphasizes the importance of structure in trading and advises on potential actions based on stock support levels and sector strength.

Talkmarkets·
US
GILD
+2.32%
US
VLO
+0.48%
US
XOM
+0.13%
Talkmarkets·
US
GILD
+2.32%
US
VLO
+0.48%
US
XOM
+0.13%

Chmn Bousbib Sells 36,564 ($8.1M) Of IQVIA Holdings Inc [IQV]

Chairman Ari Bousbib of IQVIA Holdings Inc sold 36,564 shares worth $8.1 million, as disclosed in a Form 4 filed with the SEC. The transaction occurred on December 18, 2025, with shares sold at $222.43 each. Bousbib's ending holdings are 1,350,465 shares, including both direct and indirect ownership. The sale follows an exercise of 50,000 shares at $59.90 each.

Reuters·
US
IQV
-0.82%
Reuters·
US
IQV
-0.82%
© 2025 Longbridge｜Disclaimer